Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 835-842

  Fukushima, Masakazu ^a   Sakamoto, Kazuki ^a   Ohshimo, Hideyuki ^a   Nakagawa, Fumio ^a   Taguchi, Tetsuo ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b Japan Society for Cancer Chemotherapy   (Japan)

Author keywords

5 FU; Irinotecan; l OHP; S 1; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CYCLIN DEPENDENT KINASE 4; IRINOTECAN; OXALIPLATIN; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAMPTOTHECIN; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PRODRUGS; TEGAFUR; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77957353049     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000927     Document Type: Article

References (37)

1. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 63: 1026-1030, 1989.
2. Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, Krook JE, Mailliard JA, Wiesenfeld M, Schaefer PL, Tirona MT and Moertel CG: Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15: 3320-3329, 1997.
3. Buroker TR, O'Connell MJ, SamWieand H, Krook JE, Gerstner CG and Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20, 1994.
4. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Corter-Funes A, Freyer G, Pamamichael D, LeBail H, Louvet C, Hendler D, de Brand F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
5. Chu E: The development of the FOLFOX regimens as a treatment standard of advanced colorectal cancer. Clin Colorectal Cancer 4: 292, 2005
6. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Marbo M, Lotz JP, Gilles-Amar V, Kruli KM, Carola E, Izrael V and de Gramont A: CPT-11 (irinotecan) addition to bimonthly, high dose LV and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35: 1343-1347, 1999.
7. Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Hohler T, Galle PR, Heike M and Moehler M: Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 4: 38, 2004.
8. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarissa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S and Brunetti C; Gruppo Oncologico Dell'Italia Meridionale: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875, 2005.
9. Pasetto LM, Jirillo A, Ladicicco G, Rossi E, Paris MK and Monfardini S: FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 25: 563-576, 2005.
10. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Flfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
11. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK and Miller LL: Irinotecan plus fluorouracil/ leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6: 81-91, 2001.
12. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of novel form of an oral 5-fluorouracil derivative (S-1) deirected to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two bio-chemical modulators. Anticancer Drugs 7: 548-557, 1996.
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gemestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
14. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000.
15. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83: 141-145, 2000.
16. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
17. Leichman CG: Thymidylate synthase as a predictor of response. Oncology 12: 43-47, 1998.
18. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y and Hirayama R: Simple combination of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated S-1. Int J Cancer 119: 1927-1933, 2006.
19. Guichard S, Cussac D, Hennebelle I, Bugat R and Canal P: Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73: 729-734, 1997.
20. Pavillard V, Formento P, Rostagno P, Formento JL, Fishel JL, Francoual M, Etienne MC and Milano G: Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 56: 1315-1322, 1998.
21. Mans DR, Grivicich I, Peters GJ and Schwartsmann G: Sequence-dependent frowth inhibition and DNA damage formation by the irinotecan-5-flurouracil combination in human colon carcinoma cell lines. Eur J Cancer 35: 1851-1861, 1999.
22. Cao S and Rustum YM: Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60: 3717-3721, 2000.
23. Satoh H, Ohtomo M, Ishikawa H, Kamma H, Yamashita YT, Ohtsuka M and Sekizawa K: In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats. J Exp Ther Oncol 2: 42-46, 2002.
24. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkevic E, Allain P, Louvet C and Gespach C: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8: 876-885, 1997.
25. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM and Ackland SP: Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 78: 227-253, 2000.
26. Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37: 1681-1687, 2001.
27. Okabe H, Tsujimoto H and Fukushima M: Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil. Oncol Rep 4: 685-690, 1997.
28. Spears CP, Shahinian AH and Moran RG: In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982.
29. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993.
30. Ikenaka K, Fukushima M, Nakamura H, Okamoto M, Shirasaka T and Fujii S: Metabolism of pyrimidine nucleotides in various tissues and tumor cells from rodents. Gann 72: 590-597, 1981.
31. Maehara Y, Nakamura H, Nakane Y, Kawai K, Okamoto M, Nagayama S and Shirasaka T: Activities of various enzymes of pyrimidine nucleotide and DNA synthesis in normal and neoplastic human tissues. Gann 73: 289-298, 1982.
32. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, Yonezawa H, Oyama K, Takahashi M, Saito K, Takechi T, Fukushima M and Shirasaka T: Superior antitumor activity of S-1 in tumors with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 39: 2387-2394, 2003.
33. Takechi T, Okabe H, Ikeda K, Fujioka A, Nakagawa F, Ohshimo H, Kitazato K and Fukushima M: Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Rep 14: 33-39, 2005.
34. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y and Hirayama R: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91: 1245-1250, 2004.
35. Takiuchi H, Kawabe S, Gotoh M and Katsu K: Thymidylate synthase gene expression in primary tumors predicts activity of S-1-based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res 1: 172-177, 2007.
36. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y and Thelander L: Mammalian p53R2 protein forms as active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276: 40647-40651, 2001.
37. Yeh KH, Cheng AL, Wan JP, Lin CS and Liu CC: Downregulation of thymidylate synthase expression and its steadystate mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 15: 371-376, 2004.